Cocrystal Pharma Inc
8CC
Company Profile
Business description
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
Contact
19805 North Creek Parkway
BothellWA98011
USAT: +1 877 262-7123
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
11
Stocks News & Analysis
stocks
Apple: Gemini partnership lets AI-worried investors breathe a sigh of relief
We believe a competitive—if not leading—AI feature suite will reinforce Apple’s wide-moat mobile device ecosystem.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,162.80 | 48.70 | -0.53% |
| CAC 40 | 8,330.97 | 16.23 | -0.19% |
| DAX 40 | 25,286.24 | 134.42 | -0.53% |
| Dow JONES (US) | 49,149.63 | 42.36 | -0.09% |
| FTSE 100 | 10,184.35 | 47.00 | 0.46% |
| HKSE | 26,962.54 | 37.27 | -0.14% |
| NASDAQ | 23,471.75 | 238.13 | -1.00% |
| Nikkei 225 | 53,820.46 | 520.77 | -0.96% |
| NZX 50 Index | 13,704.81 | 52.90 | -0.38% |
| S&P 500 | 6,926.60 | 37.14 | -0.53% |
| S&P/ASX 200 | 8,836.90 | 44.10 | -0.50% |
| SSE Composite Index | 4,115.32 | 10.78 | -0.26% |